America Latina Times
SEE OTHER BRANDS

The most trusted news from Latin America

America Latina Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on America Latina Times.

Press releases published on May 19, 2025

Dupla Conquista da XS.com no Traders Summit 2025: Reconhecimento por Confiança e Excelência em Saques

Dupla Conquista da XS.com no Traders Summit 2025: Reconhecimento por Confiança e Excelência em Saques

BRAZIL, May 19, 2025 /⁨Business News⁩/ -- A XS.com, provedora global de serviços financeiros e FinTech, foi destaque no Forex Traders Summit Dubai 2025, realizado nos dias 14 e 15 de maio na prestigiada Festival Arena em Dubai, ao conquistar dois prêmios …

Does Cloud Mining Really Pay? HashFly Makes It Possible with Cutting-Edge Mining Solutions

Does Cloud Mining Really Pay? HashFly Makes It Possible with Cutting-Edge Mining Solutions

New York, USA, May 19, 2025 (GLOBE NEWSWIRE) -- In the rapidly evolving world of cryptocurrency, cloud mining has emerged as one of the most sought-after methods for individuals to earn passive income. However, with so many platforms available, the …

Lazza Global Recibe Prestigioso Silver Globee® Award por su Inteligencia Artificial en Finanzas

Lazza Global Recibe Prestigioso Silver Globee® Award por su Inteligencia Artificial en Finanzas

Lazza Global es galardonada con el Silver Globee® Award 2025, reconociendo su impacto global en la transformación de la inversión mediante IA CIUDAD DE MEXICO, CDMX, MEXICO, May 19, 2025 /⁨EINPresswire.com⁩/ -- En una era donde la inteligencia artificial …

Doble triunfo para XS.com en el Traders Summit 2025: Reconocido por su Confianza y Excelencia en Retiros

Doble triunfo para XS.com en el Traders Summit 2025: Reconocido por su Confianza y Excelencia en Retiros

MEXICO, May 19, 2025 /⁨Business News⁩/ -- XS.com, proveedor global de servicios financieros y FinTech, fue protagonista en el Forex Traders Summit Dubai 2025, celebrado los días 14 y 15 de mayo en la prestigiosa Festival Arena de Dubái, al recibir dos …

Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study

Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study

- For each 5-mg/dL increase in serum TTR level within 28 days of starting treatment, the relative risk reduction of mortality was up to 31.6% through Month 30, confirming the hypothesis that ever better levels of stabilization achieved by treatment with …

NovelMed’s Phase II Data in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients: Ruxoprubart Shows Best-in-Class Efficacy as Monotherapy

NovelMed’s Phase II Data in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients: Ruxoprubart Shows Best-in-Class Efficacy as Monotherapy

--- Ruxoprubart (NM8074) met all clinical endpoints, offering a safe, differentiated treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH). Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare hematological (Blood) disorder. Regulatory approval for the …

ProSat Networks Expands Professional Starlink Installation Services in New Mexico

ProSat Networks Expands Professional Starlink Installation Services in New Mexico

ProSat Networks 1-844-799-0258 offers Starlink installation services in New Mexico for businesses, homeowners, mobile vehicles …

Metal Building Construction Contractors in Fredericksburg Texas Overcome Tariffs in Metal Building Construction with AI

Metal Building Construction Contractors in Fredericksburg Texas Overcome Tariffs in Metal Building Construction with AI

Metal Building Construction Contractors in Fredericksburg Texas and San Antonio Texas Overcome Tariff Challenges in Metal Building Construction with AI SAN ANTONIO, TX, UNITED STATES, May 18, 2025 /⁨EINPresswire.com⁩/ -- General Contractor Near Me and …

Phase II Data in Treatment-Naïve Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients: Ruxoprubart Demonstrates Best-in-Class Efficacy as Monotherapy

Phase II Data in Treatment-Naïve Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients: Ruxoprubart Demonstrates Best-in-Class Efficacy as Monotherapy

--- Ruxoprubart (NM8074) met all clinical endpoints, offering a safe, differentiated treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH). Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare hematological (Blood) disorder. Regulatory approval for the …

KixaMiner: Increase your wealth with daily passive income through cloud mining

KixaMiner: Increase your wealth with daily passive income through cloud mining

Londond, United Kingdom, May 19, 2025 (GLOBE NEWSWIRE) -- As times change, so do attitudes toward energy. The rise of renewable energy sources like solar and wind power has revolutionized cloud mining operations—significantly reducing costs while feeding …

Rani Therapeutics Announces Research Agreement with Chugai

Rani Therapeutics Announces Research Agreement with Chugai

- Research agreement is evaluating feasibility of applying Rani’s oral delivery technology to Chugai’s antibodies against undisclosed targets - SAN JOSE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “ …

Reflect Scientific Strengthens Position in Booming AI Data Center Cooling Market with Patented Cryogenic Innovations

Reflect Scientific Strengthens Position in Booming AI Data Center Cooling Market with Patented Cryogenic Innovations

OREM, Utah, May 19, 2025 (GLOBE NEWSWIRE) -- Reflect Scientific, Inc. (Symbol: RSCF), a pioneer in cryogenic cooling technologies, today highlighted how its patented solutions are uniquely positioned to address the surging global demand for advanced data …

Keros Therapeutics Highlights Commitment to Maximizing Stockholder Value

Keros Therapeutics Highlights Commitment to Maximizing Stockholder Value

Files Investor Presentation and Issues Open Letter to Stockholders Urges Stockholders to Protect the Value of Their Investment by Voting “FOR” Each of the Company’s Highly Qualified Director Nominees LEXINGTON, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Keros …

Nuvini Group Announces Participation in the Sidoti Micro-Cap Investor Conference

Nuvini Group Announces Participation in the Sidoti Micro-Cap Investor Conference

NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Nuvini Group Limited (Nasdaq: NVNI) (“Nuvini” or the “Company”), a leading acquirer of private B2B SaaS companies in Latin America, today announced that management will participate in the Sidoti Virtual Micro-Cap …

Critical Metals Corp Releases Further Excellent Deep High-Grade Drilling Results on Tanbreez (TREO 0.48% & HREO 27%)

Critical Metals Corp Releases Further Excellent Deep High-Grade Drilling Results on Tanbreez (TREO 0.48% & HREO 27%)

NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Critical Metals Corp. (Nasdaq: CRML) (“Critical Metals Corp” or the “Company”), a leading critical minerals mining company, is pleased to publish for the first time the assay results of historical deep diamond …

Doge Jones Industrial Average Partners with Indexify to Launch First Functional Memecoin Index

Doge Jones Industrial Average Partners with Indexify to Launch First Functional Memecoin Index

San Juan, PR, May 19, 2025 (GLOBE NEWSWIRE) -- The Doge Jones Industrial Average (DJI) has today announced a strategic partnership with Indexify to launch the first functional meme coin index, beginning with a curated basket of the top 10 Solana memecoins. …

Atsena Therapeutics Announces Positive Clinical Data from Part A of Phase I/II Trial Evaluating ATSN-201 Gene Therapy to Treat X-linked Retinoschisis (XLRS)

Atsena Therapeutics Announces Positive Clinical Data from Part A of Phase I/II Trial Evaluating ATSN-201 Gene Therapy to Treat X-linked Retinoschisis (XLRS)

First XLRS study to demonstrate efficacy and positive safety data in a Phase I/II trial Majority of patients demonstrated successful efficacy readouts across structural measurements (foveal schisis closure) and had meaningful improvement on visual function …

Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD)

Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD)

GAITHERSBURG, Md., May 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has enrolled the …

FEMSA Announces Accelerated Share Repurchase Agreement

FEMSA Announces Accelerated Share Repurchase Agreement

MONTERREY, Mexico, May 19, 2025 (GLOBE NEWSWIRE) -- Fomento Económico Mexicano, S.A.B. de C.V. (“FEMSA” or the “Company”) (NYSE: FMX; BMV: FEMSAUBD, FEMSAUB) today announced that, as part of its ongoing efforts and consistent with its capital allocation …

FEMSA Anuncia Acuerdo de Recompra Acelerada de Acciones

FEMSA Anuncia Acuerdo de Recompra Acelerada de Acciones

MONTERREY, México, May 19, 2025 (GLOBE NEWSWIRE) -- Fomento Económico Mexicano, S.A.B. de C.V. (“FEMSA” o la “Compañía”) (NYSE: FMX; BMV: FEMSAUBD, FEMSAUB) anunció hoy que, como parte de sus esfuerzos continuos y consistente con su estrategia de …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service